This multicenter, prospective Phase I study is aimed at testing the safety of F8IL10 via i.a. administration once every 4 weeks over 8 weeks in patients with RA who, despite treatment with stable doses (at least 3 months) of DMARDs (conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for i.a. injections.

开始日期2023-03-31

申办/合作机构

Philogen SpA

NCT03414788

/ Withdrawn临床1期

PHASE 1B, OPEN LABEL STUDY TO CHARACTERIZE THE DISTRIBUTION OF A SINGLE INTRAVENOUS DOSE OF [124I]-IODOBENZOYL (IB)-PF-06687234 WITH CONCURRENT ADMINISTRATION OF NON-RADIOLABELED PF-06687234 AS ASSESSED WITH POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PET-CT) IMAGING IN MODERATE TO SEVERE ULCERATIVE AND CROHN'S COLITIS SUBJECTS

The purpose of the study is to evaluate the PK, safety and tolerability of PF-06687234 and [124I]IB-PF-06687234 (simultaneously given) in subjects with moderate to severe Ulcerative Colitis or Crohn's Disease. The study used PET-CT scan imaging to assess the distribution of PF-06687234 and [124I]IB-PF-06687234 over 24 and 72 hours in colon (inflamed and non-inflamed), plasma, colon, liver, spleen, kidney and small intestine.

开始日期2020-12-07

申办/合作机构

Pfizer Inc.

NCT03269695

/ Terminated临床2期

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE COLITIS SUBJECTS WHO ARE NOT IN REMISSION (BUILD UC)

The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.

开始日期2017-12-20

申办/合作机构

Pfizer Inc.

100 项与 F8-IL10 相关的临床结果

登录后查看更多信息

100 项与 F8-IL10 相关的转化医学

登录后查看更多信息

100 项与 F8-IL10 相关的专利（医药）

登录后查看更多信息

项与 F8-IL10 相关的文献（医药）

2019-12-01·BMC rheumatology

Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis

Article

作者: Onuma, Kazuhiro ; Sohn, Dong H ; Kragstrup, Tue W ; Wang, Qian ; Robinson, William H ; Lepus, Christin M ; Sokolove, Jeremy

Abstract:

Background:

The pathophysiology of osteoarthritis (OA) involves wear and tear, and a state of low-grade inflammation. Tissue repair responses include transforming growth factor beta (TGFβ)-induced myofibroblast production of extracellular matrix. Fibronectins are an essential part of the extracellular matrix, and injection of fibronectin fragments into rabbit joints is a previously established animal model of OA. Fibronectin containing the ED-A domain is currently being used as drug delivery target in the development of anti-inflammatory drugs (e.g. Dekavil).

Methods:

In this study, samples of synovial membrane were obtained from patients with knee OA undergoing joint replacement surgery. Immunostaining for ED-A fibronectin and the myofibroblast marker alpha smooth muscle actin (αSMA) was performed on fibroblast-like synovial cells (FLS) and synovial membranes. RAW 264.7 macrophages were incubated with recombinant ED-A fibronectin.

Results:

The staining of ED-A fibronectin in OA FLS was increased by TGFβ but not by TNFα, lipopolysaccharide, or IL-6 (n = 3). ED-A fibronectin co-stained with the myofibroblast marker αSMA in both the OA FLS (n = 3) and in the OA synovial membranes (n = 8). ED-A fibronectin staining was associated with both number of lining layer cells (rho = 0.85 and p = 0.011) and sublining cells (rho = 0.88 and p = 0.007) in the OA synovium (n = 8), and co-distributed with TNFα (n = 5). Recombinant ED-A fibronectin increased the production of TNFα by RAW 264.7 macrophages (n = 3).

Conclusions:

The disease process in OA shares features with the chronic wound healing response. Our findings support utilizing ED-A fibronectin for drug delivery or therapeutic targeting to reduce pro-inflammatory responses in OA.

2019-01-07·Molecular pharmaceutics2区 · 医学

F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach

2区 · 医学

Article

作者: Gerrit Jansen ; Guus A M S van Dongen ; Danielle J Vugts ; Conny J van der Laken ; Adriaan A Lammertsma ; Otto S Hoekstra ; Dario Neri ; Carla F M Molthoff ; Marc C Huisman ; Durga M S H Chandrupatla ; René J P Musters ; Stefan T G Bruijnen ; Leonardo Giovanonni

Antibody fragment F8-mediated interleukin 10 (IL10) delivery is a novel treatment for rheumatoid arthritis (RA). F8 binds to the extra-domain-A of fibronectin (ED-A). In this study, in vivo biodistribution and arthritis targeting of radiolabeled F8-IL10 were investigated in RA patients, followed by further animal studies. Therefore, three RA patients (DAS28 > 3.2) received 0.4 mg of 30-74 megabecquerel [¹²⁴I]I-F8-IL10 for PET-CT and blood sampling. In visually identified PET-positive joints, target-to-background was calculated. Healthy mice, rats, and arthritic rats were injected with iodinated F8-IL10 or KSF-IL10 control antibody. Various organs were excised, weighed, and counted for radioactivity. Tissue sections were stained for fibronectin ED-A. In RA patients, [¹²⁴I]I-F8-IL10 was cleared rapidly from the circulation with less than 1% present in blood after 5 min. PET-CT showed targeting in 38 joints (11-15 per patient) and high uptake in the liver and spleen. Mean target-to-background ratios of PET-positive joints were 2.5 ± 1.2, 1.5 times higher for clinically active than clinically silent joints. Biodistribution of radioiodinated F8-IL10 in healthy mice showed no effect of the radioiodination method. [¹²⁴I]I-F8-IL10 joint uptake was also demonstrated in arthritic rats, ∼14-fold higher than that of the control antibody [¹²⁴I]I-KSF-IL10 ( p < 0.001). Interestingly, liver and spleen uptake were twice as high in arthritic than in healthy rats and were related to increased (∼7×) fibronectin ED-A expression in these tissues. In conclusion, [¹²⁴I]I-F8-IL10 uptake was observed in arthritic joints in RA patients holding promise for visualization of inflamed joints by PET-CT imaging and therapeutic targeting. Patient observations and, subsequently, arthritic animal studies pointed to awareness of increased [¹²⁴I]I-F8-IL10 uptake in the liver and spleen associated with moderate systemic inflammation. This translational study demonstrated the value of in vivo biodistribution and PET-CT-guided imaging in development of new and potential antirheumatic drugs'.

2015-09-01·International journal of cardiology2区 · 医学

Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human antibody specific to the extra domain A of fibronectin

2区 · 医学

Article

作者: Köse, Nilay ; Jung, Christian ; Ziffels, Barbara ; Franz, Marcus ; Richter, Petra ; Doll, Fabia ; Figulla, Hans R ; Gummert, Jan ; Grün, Katja ; Schubert, Harald ; Berndt, Alexander ; Neri, Dario ; Renner, André

BACKGROUND AND AIMS:

Management of chronic rejection is challenging since there are not sufficient preventive or therapeutic strategies. The rejection process leads to overexpression of ED-A(+) fibronectin (ED-A(+) Fn). The human antibody F8, specific to ED-A(+) Fn, may serve as a vehicle for targeted delivery of bioactive payloads, e.g. interleukin 10 (IL-10). The aim of this study was to investigate the therapeutic effects of the fusion protein F8-interleukin-10 (F8-IL10) in the process of chronic rejection development.

METHODS:

A heterotopic rat heart transplantation model was used to induce chronic rejection. For therapeutic interventions, the immunocytokines F8-humanIL10 (DEKAVIL), F8-ratIL10 as well as KSF-humanIL10 (irrelevant antigen-specificity) were used. Treatment was performed weekly for 10 weeks starting at day 7 after transplantation (1mg/animal).

RESULTS:

In the cardiac allografts, treatment with F8-huIL10 or F8-ratIL10 was associated with increased heart weights, a higher grade of chronic rejection, increased CIF, higher protein expression levels of alpha-smooth muscle actin (α-SMA), an augmented infiltration with inflammatory cells (CD4+, CD8+ and CD68+ cells) and higher serum levels of brain natriuretic peptide (BNP) compared to the control groups.

CONCLUSIONS:

All observed treatment effects are transplantation-specific since the F8 antibody is specific to ED-A(+) Fn that is not expressed in healthy hearts. A clear targeting effect of F8-huIL10 as well as F8-ratIL10 could be proven. Against that background, a further study is needed to address the question, if F8-IL10 treatment is capable to reduce CAV and CIF starting at a time point when chronic rejection has fully developed (therapeutic approach).

项与 F8-IL10 相关的新闻（医药）

2024-07-22

·药智网

「蛋白偶联」创新：细胞因子只是开始，PEG/mPEG修饰才是未来

有目共睹，ADC药物已是继PD-1单抗肿瘤药之后，肿瘤研发领域的最大热点。而随着越来越多ADC药物的持续上市，全球ADC市场规模也在快速增长。但是，ADC药物逐渐内卷的竞争趋势下，在价值百亿的ADC市场赛道中，如何跑出差异化，却成为每个玩家都迫切面临的难题。为此，有的企业选择在靶向分子上下功夫，避开抗体，以多肽、小分子等新的靶向载体为突破，诞生了PDC、SMDC等区别于ADC的技术类型；而另一些企业却将差异化目光放到了有效载荷之上，利用有效载荷的多样化来凸显差异化。比如以放射性核素、PROTAC分子作为有效载荷的新技术，以各种“药效蛋白”作为治疗性payload的大胆尝试。蛋白效应偶联物优势明显所谓蛋白效应偶联物，即将药效蛋白（细胞因子、蛋白毒素与免疫细胞）与靶向性分子链接在一起，在原来药效蛋白的基础上增加靶向性或其他，减少药效蛋白的系统性毒性，其原理上与熟知的ADC机理相似，在兼具了药效蛋白与偶联药物的特点的同时，也有其特殊优势：相较传统药效蛋白，蛋白效应偶联物理论上可以拥有更强的有效性、更低的毒副作用、更特异性的靶点与更高的效价，当其与化疗、放疗等其他抗肿瘤治疗方式结合时，抗肿瘤特性还会显著增强。而相较传统ADC，蛋白效应偶联物可以拥有更强的靶向毒性，更广的适应范围，可以应用于更多非肿瘤领域，如多数自免疾病。现在来看，靶向分子与药效蛋白发挥协同效应，明显可以产生1+1＞2的作用，达成更高效的治疗需求。但同时，由于药效蛋白与靶向分子的诸多链接限制，对于蛋白偶联物领域而言，也有不少值得进一步研究的内容。细胞因子药效蛋白偶联物的开始就现阶段而言，药效蛋白作为效应分子在偶联药物领域的例子并没有想象中那么多，近年来陆续出现的蛋白毒素、细胞因子与免疫细胞已是较为前沿的研究成果，而其中又以“细胞因子偶联物”的研究最具代表性。过去几十年，随着细胞因子的持续发现，其被广泛应用于抗肿瘤与抗感染方面，但与此同时，应用越广，其凸显出的局限性也越强，比如半衰期短，治疗窗口窄，毒副作用大等，这普遍存在于多数药效蛋白中。而抗体偶联细胞因子（immunocytokine），即通过特异性抗体将细胞因子引导至肿瘤微环境等疾病局部，再由细胞因子发挥其作用（如激活或者抑制免疫细胞），如此一来，可以有效降低肿瘤外毒性，以此扩大细胞因子的治疗窗口，因而，近年来也有越来越多的“抗体偶联细胞因子”相继进入临床阶段。品种原研单位许可单位靶点临床阶段 Nidlegy Philogen SpA 印度太阳药业有限公司 TNFA;EDB-FN;IL-2 注册申请 L19-TNF;Fibromun Philogen SpA - TNFA;EDB-FN 临床Ⅲ期 IBI-363 信达生物制药（苏州）有限公司 - IL-2;PD-1 临床Ⅱ期 RO6874281;simlukafusp alfa 罗氏制药 - AFAP1L2;FAP-alpha;IL-2 临床Ⅱ期 SAR-445877 赛诺菲 - IL15;PD-1 临床Ⅱ期 OXS-3550 University of Minnesota OXIS International Inc IL15;CD16;CD33 临床Ⅱ期 PF-06687234 Philogen SpA 辉瑞公司 IL10;CD29;EDA-FN 临床Ⅱ期 IBB-0979 盛禾（中国）生物制药有限公司 - IL10;CD276 临床Ⅱ期 SNG-2005 EMD Lexigen Research Center Corp;EMD Serono Inc Alopexx Oncology LLC CD20 临床Ⅱ期 APN-301 Apeiron Biologics GmbH;默克 - IL-2 临床Ⅱ期 ANV-419 Anaveon AG;University of Zurich - IL-2 临床Ⅱ期 TAK-573 武田药品工业株式会社 - IFN-alpha-2;CD38 临床Ⅱ期 Darleukin;L19-IL2 Philogen SpA Maastricht University Medical Center EDB-FN;IL-2 临床Ⅱ期 NHS-IL2-LT 默克 - IL-2;IL2R 临床Ⅱ期 STAR-0602 Marengo Therapeutics - TCRBV 临床Ⅱ期 RG-7835 罗氏制药 - CD25 临床Ⅱ期 IAE-0972 盛禾（中国）生物制药有限公司 - IL10;EGFR 临床Ⅱ期 F16IL2 PhiloGene Inc - IL-2;Tenascin 临床Ⅱ期 M-9241 默克 National Cancer Institute IL12R 临床Ⅱ期 PDS0301 PDS Biotechnology Corp - IL-12 临床Ⅱ期 IAP-0971 盛禾（中国）生物制药有限公司 - IL15;PD-1 临床Ⅱ期数据来源：药智数据截至目前，全球已有数十款在研的抗体偶联细胞因子药物，其有效载荷主要集中在IL-2，IFN-γ，EPO等类型。其中由Philogen开发的Nidlegy是抗体偶联细胞因子领域中进度最靠前的管线，目前已向欧洲药品管理局（EMA）提交了上市申请，一旦获批，或将成为第一款上市的抗体偶联细胞因子产品。而作为 Philogen 专有的生物制药产品，Nidlegy是专为治疗皮肤癌而设计。结构上由 L19IL2 和 L19TNF 组成，其中L19 抗体对纤连蛋白的额外结构域 B 具有特异性，其Ⅲ期PIVOTAL研究显示，治疗组复发或死亡风险降低了41%，中位RFS延长了一倍以上，且患者组实现病理学完全缓解（pCR）的比例为21%。而国内领域，研究进度较靠前的则是信达生物的一款PD-1/IL-2（IBI363），其采取非对称二聚体设计，IL-2经过改造保留CD25（IL2Rɑ）活性以最大化疗效和高选择性，同时减少对Rβγ 结合以降低系统毒性。既可以阻断PD-1/PD-L1免疫抑制通路，又可以通过IL-15激活免疫细胞；同时，PD-L1抗体还能将IL-15靶向到PD-L1+的肿瘤微环境，选择性激活肿瘤浸润CD8+T细胞和NK细胞，降低IL-15全身性副作用。综上可知，抗体偶联细胞因子的技术方向，因其强大的靶向肿瘤和延长细胞因子半衰期的能力，以及其对多个靶点的协同抗肿瘤作用，目前已经成为效应蛋白偶联物领域最具前景的疗法，成了创新biotech脱颖而出的重要资本。不过，尽管表面上看抗体偶联细胞因子领域似乎前景广阔，但对于“药效蛋白偶联物”领域而言，仍是成功的个别例子，占据极小的部分，放眼整个药效蛋白偶联领域，仍有大量药效蛋白缺乏有效的偶联方式。化学修饰+蛋白药效蛋白偶联物的未来就技术层面而言，如何想将任一蛋白进行修饰偶联，而不需要考虑药效蛋白的针对性与特殊性，是现阶段专家在研究中主要的思考方向。目前来看，通过化学偶联修饰方式与药效蛋白相结合是比较切实可行的方法。比如PEG/mPEG修饰、氨甲酰化修饰、硫酸化修饰与磷酸化修饰。 PEG/mPEG偶联蛋白所谓PEG，是一种被广泛应用于蛋白质和多肽等生物聚合物进行共价修饰的高分子材料；mPEG则是将PEG其中一端进行封端后的产物；而PEG/mPEG化修饰就是将其与药物共价结合，以改善药物的药代动力学、药效学和免疫学特性，从而增强其治疗效果的一种药物技术。通常情况下，PEG/mPEG由于提高水溶性、减少酶水解、降低毒性和免疫原性、延长体内半衰期、改变组织分布以及增加药物分子的靶向位点浓度等特点，被主要考虑用作生物分子偶联的起始材料。图片来源：西宝生物而在众多与PEG偶联的生物大分子中，脂类、蛋白质、小分子药物和其他疏水性聚合物已被广泛研究，并被用来制造用于药物输送和成像的纳米载体，对于蛋白质而言，其没有对蛋白种类的显示，简单来讲就是局限于细胞因子、免疫细胞等种类，理论上可以与所有蛋白质进行PEG偶联。在原理上，蛋白质的PEG修饰之所以有一系列优势，主要是由于蛋白质PEG修饰后，偶联物使原有蛋白质的分子量增大，空间结构发生改变，一方面可以是使其可以逃避肾小球滤过作用，在血液循环中停留更长的时间；另一方面修饰剂会使得蛋白质表面抗原决定簇掩盖起来，避开免疫系统识别；甚至修饰剂作用下，蛋白质药物还能不易被各种蛋白酶的攻击，降解速率明显降低。图注：聚乙二醇修饰蛋白示意图资料来源：键凯科技招股说明书从蛋白质PEG修饰到mPEG修饰，如今在该领域范围内，已经有了许多蛋白质的聚乙二醇化修饰物作为药物取得了较好的结果，可行性上得到了充分验证。 1991年，第一种经聚乙二醇化修饰的蛋白质类药物PEG-腺苷脱氨酶被FDA批准上市，用于治疗一种严重的儿童免疫缺陷症； 2001年，用聚乙二醇修饰的干扰素（PEG-INTRON）经FDA批准上市，用于治疗慢性丙型肝炎； 2010年，通过赖氨酸偶联进行聚乙二醇化的普瑞凯希Krystexxa（pegloticase）被FDA批准用于治疗痛风，实现每月一针的注射频率。 2024年，J.P. Morgan大会上，由 Ascendis Pharma 原研开发的一款在研 PTH 激素原药（TransCon PTH ）亮相，由母药 PTH(1-34) 和支链甲氧基聚乙二醇 (mPEG) 载体通过专有连接剂瞬时结合而成，正在开发用于治疗成人甲状旁腺功能减退症，可以实现24 小时的正常生理范围内提供稳定的 PTH 水平。并且，作为化学偶联修饰中最主要的存在，PEG/mPEG修饰还成功为化学修饰蛋白建立了良好的开端，也为后续企业更多在研化学修饰方法，提供了良好的模板，比如氨甲酰化、硫酸化、磷酸化等。小结总结来看，由于药效蛋白本身诸多优势，目前通过偶联方式将药效蛋白进行系列改装已成为了现实，最切实有用的方法可以参考“抗体+蛋白毒素、抗体+细胞因子”。但是，无论是细胞因子、蛋白毒素，还是免疫细胞，其都只能代表药效蛋白中较小部分，蛋白偶联仍存在明显的局限性与针对性，好在以PEG/mPEG为首的化学偶联修饰技术之下，研究者们似乎在寻找针对任何蛋白偶联方法上已经有了些许突破。未来，随着更多如PEG/mPEG化、氨甲酰化、硫酸化、磷酸化等化学偶联修饰方法的发现，整个药效蛋白市场或许也将发生巨大重构，我们拭目以待。来源 | 博药（药智网获取授权转载）撰稿 | 头孢责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

抗体药物偶联物多肽偶联药物蛋白降解靶向嵌合体

2023-01-09

·PRNewswire

Rheumatoid Arthritis Market is Expected to Showcase Significant Growth in the 7MM at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Predicts DelveInsight

The dynamics of the rheumatoid arthritis market are anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities. Companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Aclaris Therapeutics [Zunsemetinib (ATI-450)], Abivax [ABX464], and others with their key candidates are in the late clinical and filing stage. LAS VEGAS, Jan. 9, 2023 /PRNewswire/ -- DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Rheumatoid Arthritis Market Report As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately USD 27 billion in 2021. According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately 4. 7 million in 2021. Leading rheumatoid arthritis companies such as Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others are developing novel rheumatoid arthritis drugs that can be available in the rheumatoid arthritis market in the coming years. The promising rheumatoid arthritis therapies in the pipeline include Ozoralizumab (TS-152), Artlegia (Olokizumab), Otilimab (GSK3196165/MOR103), Zunsemetinib (ATI-450), Ritlecitinib (PF-06651600), ABX464, Branebrutinib, Cevidoplenib (SKI-O-703), MPC-300-IV, PF-06650833, JTE -051, ABBV-154, TAS5315, MBS2320, AMT-101, AP1189, Rabeximod (Rob 803), and others. In June 2022, Cyxone received a response from a Type B Pre-IND meeting with the US FDA. The response from the FDA facilitates Cyxone to continue planning the Phase IIb study with Rabeximod in RA. In December 2021, Taisho Pharmaceuticals presented the interim results from a 24-week administration in Phase II/III clinical trial (OHZORA study) of ozoralizumab in adult patients with RA at the annual meeting of the Japanese Society for Clinical Rheumatology and Related Research. Discover which therapies are expected to grab the major rheumatoid arthritis market share @ Rheumatoid Arthritis Market Report Rheumatoid Arthritis Overview Rheumatoid arthritis is a type of autoimmune disease. It happens when our immune system, which is supposed to defend us, malfunctions and starts attacking our own tissues. It causes inflammation in the joint lining (the synovium). As a result, joints may become red, warm, swollen, and painful, which are all symptoms of rheumatoid arthritis. The precise causes of rheumatoid arthritis are still unknown. Because the early signs and symptoms of rheumatoid arthritis are similar to those of many other diseases, it can be difficult to detect in its early stages. There is no single blood test or physical finding that can confirm the diagnosis of rheumatoid arthritis. There is no known cure for rheumatoid arthritis. However, clinical trials of rheumatoid arthritis show that remission of symptoms is more common when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines begins early (DMARDs). Rheumatoid Arthritis Epidemiology Segmentation DelveInsight estimates that there were approximately 4.7 million prevalent cases of rheumatoid arthritis in the 7MM in 2021. Among the EU4 and the UK countries, Germany accounted for the highest number of rheumatoid arthritis cases, whereas France accounted for the lowest cases in 2021 The rheumatoid arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalent Cases Total Diagnosed Prevalent Cases Gender-specific Prevalent Cases Age-specific Prevalent Cases Severity-specific Prevalent Cases Patients on Targeted Therapies Line-Wise Treated Cases Download the report to understand which factors are driving rheumatoid arthritis epidemiology trends @ Rheumatoid Arthritis Epidemiological Insights Rheumatoid Arthritis Treatment Market Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are Medicine (for long-term relief of symptoms and slowing the progression of the condition), Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and Surgery (to correct any joint problems that develop over a period of time). Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression. Moreover, disease-modifying antirheumatic drugs (DMARDs) are used to target inflammation and prevent further joint damage and disease progression. DMARDs are a class of drugs that have been shown to affect the underlying cause of rheumatoid arthritis by reducing immune system overactivity, thereby alleviating pain, swelling, and stiffness and preventing joint changes. DMARDs can be prescribed singly or in combination as an initial part of treatment. Methotrexate is the first-line DMARD agent for the majority of rheumatoid arthritis patients. It has a relatively quick onset of action at therapeutic doses (6-8 weeks), good efficacy, a low toxicity profile, is easy to administer, and is relatively inexpensive. To know more about rheumatoid arthritis guidelines, visit @ Rheumatoid Arthritis Management Rheumatoid Arthritis Pipeline Therapies and Key Companies Artlegia (Olokizumab): R-Pharm TS-152 (Ozoralizumab): Taisho Pharmaceuticals Otilimab (GSK3196165/MOR103): GlaxoSmithKline ATI-450 (Zunsemetinib/CDD-450): Aclaris Therapeutics Branebrutinib: Bristol Myers Squibb LY3462817: Eli Lilly and Company TAS5315: Taiho Pharmaceutical Rabeximod (Rob 803): Cyxone GS-5718: Gilead Sciences KPL-404: Kiniksa Pharmaceuticals MBS2320: Istesso AMT-101: Applied Molecular Transport Dazodalibep (HZN-4920): Horizon Therapeutics Cevidoplenib (SKI-O-703): Genosco/Oscotec HB-AdMSCs: Hope Biosciences ABX464: Abivax MPC-300-IV: Mesoblast PF-06650833: Pfizer JTE 051: Akros Pharma/Japan Tobacco Dekavil (F8IL10): Pfizer/Philogen ABBV-154: AbbVie PF-06651600 (Ritlecitinib): Pfizer AP1189: SynAct Pharma Learn more about the FDA-approved drugs for rheumatoid arthritis @ Drugs for Rheumatoid Arthritis Treatment Rheumatoid Arthritis Market Dynamics The dynamics of the rheumatoid arthritis market is anticipated to change in the future due to the increasing awareness and expected increase in investment in the R&D activities by the leading companies working in the rheumatoid arthritis market space. Moreover, current therapies, such as biological DMARDs, have shown promising results in treating rheumatoid arthritis patients, and market penetration is expected to increase in the future, driving rheumatoid arthritis market growth. Furthermore, there is still a high demand for therapies with a similar efficacy profile to current therapies but a better safety profile and a more patient-friendly RoA. Oral classes, such as JAKi and the upcoming BTKi, are expected to contribute to the rheumatoid arthritis market growth due to patient-friendly RoA. However, several factors are likely to hamper the rheumatoid arthritis market growth. The rheumatoid arthritis market is highly competitive, and new entrants are expected to face some resistance and low uptake because anti-TNFs currently dominate the rheumatoid arthritis market, and the entry of biosimilars will pose significant challenges to new and upcoming treatment options in the rheumatoid arthritis market. In addition, the entry of biosimilars has already begun in the US and EU (i.e., Remicade biosimilars), and as a result, sales value has started to decline. The impact will be more pronounced when biosimilars/ generics of some blockbuster drugs, such as Humira (i.e., 2023 in the US), Xeljanz (i.e., 2025 in the US), will enter the rheumatoid arthritis market, and this will significantly impact the growth of the rheumatoid arthritis market. Scope of the Rheumatoid Arthritis Market Report Therapeutic Assessment: Rheumatoid Arthritis current marketed and emerging therapies Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement Discover more about rheumatoid arthritis drugs in development @ Rheumatoid Arthritis Clinical Trials Table of Contents Related Reports Rheumatoid Arthritis Epidemiology Forecast Rheumatoid Arthritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted rheumatoid arthritis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Juvenile Rheumatoid Arthritis Pipeline Juvenile Rheumatoid Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key juvenile rheumatoid arthritis companies, including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Juvenile Rheumatoid Arthritis Market Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies, including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Psoriatic Arthritis Pipeline Psoriatic Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including Mylan, Celltrion, Pfizer, Amgen, among others. Psoriatic Arthritis Market Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies, including Mylan, Celltrion, Pfizer, Amgen, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market Related Healthcare Blogs Rheumatoid Arthritis Emerging Drugs Knee Osteoarthritis Pipeline Rheumatoid Arthritis Market Scenario Juvenile Idiopathic Arthritis Therapy Market Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

临床结果

2022-07-26

·PRNewswire

New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsight

Rise in prevalence of rheumatoid arthritis, increase in demand for rheumatoid arthritis drugs, the entry of biosimilar drugs, the surge in geriatric population are the key factors driving the development of potential treatment of Rheumatoid arthritis. Major key players include Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, and others. LAS VEGAS, July 26, 2022 /PRNewswire/ -- DelveInsight's ' Rheumatoid Arthritis Pipeline Insight 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline rheumatoid arthritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the rheumatoid arthritis pipeline domain. Key Takeaways from the Rheumatoid Arthritis Pipeline Report DelveInsight's rheumatoid arthritis pipeline report depicts a robust space with 120+ active players working to develop 120 + pipeline therapies for rheumatoid arthritis treatment. Key rheumatoid arthritis companies such as Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others are evaluating novel rheumatoid arthritis treatment drugs candidate to improve the treatment landscape. Promising rheumatoid arthritis pipeline therapies in various stages of development includes TS152, HS-016, SM03, SHR0302, RC18, Otilimab, NI-0101, MBS2320, KN019, JTE-051, Interleukin 2, HL237, GLPG3970, Elsubrutinib, CKD-506, Branebrutinib, AZD9567, ATI-450, ABX464, ABBV 3373, ABBV 154, AP1189, F8IL10, AMT-101, GS-9876, CR 6086, LY 3462817, KPL-404, Orticumab, Rabeximod, YRA 1909, VIB4920, Varicella Zoster Vaccine, TAS5315, SKI-O-703, SAN-300, PF-06650833, Nipocalimab, CF-101, A223, IRL 201805, LNK 01001, PRTX-100, hUC-MSC infusion, HB-adMSC, LABP-104, VAY736, TJ003234 , SYN060, GS-5718, PF-06835375, Nivolumab, MH004, ORTD-1, ART-I02, FB704A, Amilo 5MER, CKD-374 , CFZ-533, BAY 1830839, AMG 570, JNJ-4703, CT-P47, BZ068, Invossa, LABP-69, ICM-203-R, NX-5948, KT-474 , Clarithromycin/clofazimine/rifabutin (RHB-104), Research programme: small molecule TYK2 inhibitors, MRx0006, CV6 1271, VYN201, MYMD-1, BBI 02, Research Programme: Immune mediated diseases, Foralumab, SPU-21, SFA002, NTR-441, Research programme: autoimmune disease therapeutics, AT_1001, MSB11456, MabionCD20, DMB-3113, GB232, GBS 005, TX17, BX 2922, Cinnora, AVT02, MYL-1401A, and others. In July 2022, Enosi Therapeutics, announced a partnership with Danuo Science Group, based in Hong Kong, to further develop two products currently in Enosi's pipeline for Greater China. Enosi's Growth Factor Trap (EN-2000 Program) and TNFR1 Blocker (EN-1000 Program) were licensed as part of the partnership. Both programs have the potential to be used as cross-over drugs to treat cancer and autoimmune diseases. EN-2000 blocks inflammatory growth factors that drive cancer and rheumatoid arthritis while EN-1000 is a specific blocker of TNFR1, which Enosi believes may be useful in treating autoimmune disease. In February 2022, Biogen Inc. and Xbrane Biopharma AB announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane™, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® (certolizumab pegol). In June 2022, Biogen Inc. and Bio-Thera Solutions, Ltd. presented positive Phase III data for BIIB800 (BAT1806), a biosimilar candidate referencing. The double-blind 52-week Phase III study randomized 621 patients with moderate to severe rheumatoid arthritis to receive either BIIB800 or the reference tocilizumab administered intravenously every 4 weeks at a dose of 8 mg/kg for the first 24 weeks. Data from the Phase III comparative clinical trial demonstrated that the investigational biosimilar candidate BIIB800 has equivalent efficacy and comparable safety and immunogenicity profile to the reference tocilizumab product. In June 2022, Revolo Biotherapeutics announced that it was awarded an Innovative Medicines Designation, or Innovation Passport, from the Medicines and Healthcare products Regulatory Agency (MHRA) for its immune-resetting drug candidate, '1805, for the treatment of patients with moderately to severely active Rheumatoid Arthritis (RA). In February 2022, Revolo Biotherapeutics secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate two Phase II trials of its autoimmune disease drug candidate '1805. One of the trials will enrol moderate-to-severe active rheumatoid arthritis (RA) patients while another Phase II trial will have individuals with non-infectious, active, intermediate, or posterior uveitis or panuveitis. In December 2021, Theramex, entered into an agreement with Enzene Biosciences Limited to develop, register, and commercialize a biosimilar drug of Roche's reference medicine RoActemra (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialized from 2026 in Europe, the UK, Switzerland, and Australia. Obefazimod is an oral, first-in-class, small molecule being developed by Abivax in Phase II stage of development. Obefazimod generated promising pre-clinical data from collagen-induced arthritis animal models that were the basis for moving into the Phase IIa clinical trial in rheumatoid arthritis (RA). Zunsemetinib, an Investigational Oral MK2 Inhibitor, is being developed by Aclaris Therapeutics. Aclaris initiated study activities and began activating sites in December 2021 in the following two studies: ATI-450-RA-202: Phase IIb clinical trial of zunsemetinib in subjects with moderate to severe rheumatoid arthritis (RA). This is Aclaris' second Phase II clinical trial of zunsemetinib in subjects with moderate to severe RA and is primarily designed to assess the efficacy of multiple doses of zunsemetinib to aid in the selection of an optimal dose to progress in future development. Request a sample and discover the recent advances in rheumatoid arthritis treatment @ Rheumatoid Arthritis Pipeline Outlook The rheumatoid arthritis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage rheumatoid arthritis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the rheumatoid arthritis pipeline landscape. Rheumatoid Arthritis Overview Rheumatoid arthritis is classified as an autoimmune disorder. It occurs when the immune system, which is supposed to defend, malfunctions and begins to attack our own tissues. It causes inflammation in the lining of the joints (the synovium). As a result, joints may become red, warm, swollen, and painful, which are common rheumatoid arthritis symptoms. The exact rheumatoid arthritis causes are still unknown. Rheumatoid arthritis can be difficult to detect in its early stages since the early signs and symptoms are similar to those of many other diseases. There is no single blood test or physical finding that can validate the rheumatoid arthritis diagnosis. Rheumatoid arthritis has no known cure. However, rheumatoid arthritis clinical trials show that remission of symptoms is more frequent when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines started early (DMARDs). Find out more about rheumatoid arthritis treatment @ Rheumatoid Arthritis Treatment Drugs A snapshot of the Rheumatoid Arthritis Pipeline Drugs mentioned in the report: Learn more about the novel and emerging rheumatoid arthritis pipeline therapies @ Rheumatoid Arthritis Clinical Trials Rheumatoid Arthritis Therapeutics Assessment The rheumatoid arthritis pipeline report proffers an integral view of rheumatoid arthritis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Rheumatoid Arthritis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-ocular, Intra-articular, Intrathecal, Intravenous, Oral, Parenteral, Ophthalmic, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: Interleukin 6 inhibitor, Tumour necrosis factor-alpha inhibitor, CD22 antigen inhibitor, Janus kinase 1 inhibitor, B cell activating factor inhibitor, Granulocyte-macrophage colony-stimulating factor antagonist, Toll-like receptor 4 antagonist, Emt protein-tyrosine kinase inhibitor, Fibroblast growth factor modulators; T lymphocyte inhibitors, Bacteria replacements. Key Rheumatoid Arthritis Companies: Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Amgen, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others Key Rheumatoid Arthritis Pipeline Therapies: TS152, HS-016, SM03, SHR0302, RC18, Otilimab, NI-0101, MBS2320, KN019, JTE-051, Interleukin 2, HL237, GLPG3970, Elsubrutinib, CKD-506, Branebrutinib, AZD9567, ATI-450, ABX464, ABBV 3373, ABBV 154, AP1189, F8IL10, AMT-101, GS-9876, CR 6086, LY 3462817, KPL-404, Orticumab, Rabeximod, YRA 1909, VIB4920, Varicella Zoster Vaccine, TAS5315, SKI-O-703, SAN-300, PF-06650833, Nipocalimab, CF-101, A223, IRL 201805, LNK 01001, PRTX-100, hUC-MSC infusion, HB-adMSC, LABP-104, VAY736, TJ003234 , SYN060, GS-5718, PF-06835375, Nivolumab, MH004, ORTD-1, ART-I02, FB704A, Amilo 5MER, CKD-374 , CFZ-533, BAY 1830839, AMG 570, JNJ-4703, CT-P47, BZ068, Invossa, LABP-69, ICM-203-R, NX-5948, KT-474 , Clarithromycin/clofazimine/rifabutin (RHB-104), Research programme: small molecule TYK2 inhibitors, MRx0006, CV6 1271, VYN201, MYMD-1, BBI 02, Research Programme: Immune mediated diseases, Foralumab, SPU-21, SFA002, NTR-441, Research programme: autoimmune disease therapeutics, AT_1001, MSB11456, MabionCD20, DMB-3113, GB232, GBS 005, TX17, BX 2922, Cinnora, AVT02, MYL-1401A, and others. Dive deep into rich insights for drugs for rheumatoid arthritis, visit @ Rheumatoid Arthritis Medications Table of Contents For further information on the rheumatoid arthritis pipeline therapeutics, reach out @ Drugs for Rheumatoid Arthritis Related Reports Rheumatoid Arthritis Market Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies including Abivax, UCB, Sierra Oncology, Taisho, among others. Rheumatoid Arthritis Epidemiology Forecast Rheumatoid Arthritis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted rheumatoid arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Juvenile Rheumatoid Arthritis Pipeline Juvenile Rheumatoid Arthritis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products and the key juvenile rheumatoid arthritis companies, including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Juvenile Rheumatoid Arthritis Market Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies including Novartis, AbbVie, Eli Lilly and Company, Sanofi, among others. Psoriatic Arthritis Pipeline Psoriatic Arthritis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriatic arthritis companies, including Mylan, Celltrion, Pfizer, Amgen, among others. Psoriatic Arthritis Market Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies including Mylan, Celltrion, Pfizer, Amgen, among others. Other Trending Reports Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market Latest Healthcare Blogs Knee Osteoarthritis Pipeline Rheumatoid Arthritis Market Scenario Juveline Idiopathic Arthritis Therapy Market About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

100 项与 F8-IL10 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
溃疡性结肠炎	临床2期	美国	Pfizer Inc.	2017-12-20
溃疡性结肠炎	临床2期	澳大利亚	Pfizer Inc.	2017-12-20
溃疡性结肠炎	临床2期	比利时	Pfizer Inc.	2017-12-20
溃疡性结肠炎	临床2期	德国	Pfizer Inc.	2017-12-20
溃疡性结肠炎	临床2期	以色列	Pfizer Inc.	2017-12-20
溃疡性结肠炎	临床2期	意大利	Pfizer Inc.	2017-12-20
溃疡性结肠炎	临床2期	沙特阿拉伯	Pfizer Inc.	2017-12-20
溃疡性结肠炎	临床2期	塞尔维亚	Pfizer Inc.	2017-12-20
溃疡性结肠炎	临床2期	土耳其	Pfizer Inc.	2017-12-20
类风湿关节炎	临床2期	德国	Philogen SpA	2014-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03269695 (BUILD UC, CTgov)	临床2期	溃疡性结肠炎	20	Placebo+Infliximab (Placebo + Infliximab)	廠鹽廠淵選蓋餘壓襯淵 = 鏇遞壓醖鹽製選蓋鑰糧獵衊廠鏇窪範餘艱夢構 (鬱衊構繭窪餘衊鏇艱網, 艱衊鬱獵齋廠積獵製鑰 ~ 築壓觸鏇壓蓋鹽蓋糧憲) 更多	-	2021-12-28
NCT03269695 (BUILD UC, CTgov)	临床2期	溃疡性结肠炎	20	Infliximab+PF-06687234 (PF-06687234 20 mg + Infliximab)	廠鹽廠淵選蓋餘壓襯淵 = 餘淵築蓋鏇構觸襯鹹蓋獵衊廠鏇窪範餘艱夢構 (鬱衊構繭窪餘衊鏇艱網, 壓構簾鬱憲鬱憲選醖繭 ~ 鏇壓醖遞壓艱獵鬱獵築) 更多	-	2021-12-28
NCT02076659 (EULAR 12018 \| EULAR 22018) 人工标引	临床2期	类风湿关节炎	-	F8-IL10	構夢糧網製繭鏇構網獵(衊膚製壓簾膚繭艱蓋襯) = 憲鬱餘艱顧醖鏇積淵廠構糧鑰鹽餘鹹衊鬱憲範 (餘蓋夢鏇廠網網鹽糧窪 )	积极	2018-06-15
EULAR2017	临床2期	类风湿关节炎	87	Dekavil (F8IL10) + MTX	糧憲淵鬱顧構範廠艱繭(積鏇醖製膚築鏇廠觸築) = 窪選廠鏇鬱醖網艱築遞構膚網觸醖積餘糧衊衊 (鹹築繭醖夢窪膚膚衊齋 ) 更多	积极	2017-06-14
EULAR2016	临床1/2期	类风湿关节炎 anti-TNFα treatment	-	Dekavil 6 μg/kg	顧膚艱襯鑰艱夢壓遞簾(齋蓋網膚窪築鑰選獵獵) = 醖繭淵積艱繭範積醖淵壓膚觸選鑰網齋窪構膚 (選繭壓憲願醖遞糧鬱觸 ) 更多	积极	2016-06-08
F8-IL10 (EULAR2015)	临床1期	类风湿关节炎 anti-TNFα drug therapy	-	Dekavil	醖淵築願獵獵憲鏇鹹鹽(遞顧襯遞築鏇繭夢鹹積) = 築夢鏇鬱醖選積窪餘壓襯窪壓構襯壓壓鏇糧艱 (築憲鑰築餘憲顧獵獵齋 ) 更多	积极	2015-06-10
SNMMI2015	N/A	-	-	124I-Dekavil	顧遞網憲簾構鹹膚簾憲(範齋糧憲選築鏇餘獵願) = 鹹鏇觸製構遞醖築鹹襯廠顧鑰遞廠築製鏇襯願 (遞鏇艱鹽鹽鏇襯糧壓襯 ) 更多	-	2015-05-15